INTRODUCTION Superficial cutaneous fungal infections (SCFIs) are commonly encountered in clinical practice in the United States, and comprise infections of the skin by dermatophytes and yeasts.1-3 Although SCFIs are seldom…
Read More
INTRODUCTIONSuperficial fungal infections – those affecting the skin, hair and nails – are extraordinarily common worldwide. About 20% to 25% of the world’s population will be affected by at least…
Read More
INTRODUCTION In the US, tinea pedis is the most common inflammatory fungal infection that is mostly caused by dermatophytes.1 These are the skin, hair, and nail-preferring fungi such as Trichophyton…
Read More
INTRODUCTION Psoriasis is a chronic, inflammatory skin condition that affects 3.2% of the US population.1 A significant portion of patients with psoriasis have scalp and nail involvement. It has been…
Read More
INTRODUCTION Despite the number of available treatments, not all patients with onychomycosis are cured and recurrence (relapse or re-infection) is not uncommon, with percentages reported in various clinical studies ranging…
Read More
INTRODUCTION Actinic keratoses (AK) are part of a disease continuum that can progress from initial keratinocyte dysplasia to invasive squamous cell carcinoma (SCC).1 Ultraviolet light affects the entire sun-exposed area…
Read More
INTRODUCTION Psoriasis is a common, chronic immune-mediated inflammatory skin disorder with potential systemic complications. Current epidemiological studies demonstrate a prevalence of 0.45-4.6% worldwide, with both ethnic and genetic factors strongly…
Read More
INTRODUCTION Psoriasis is a chronic inflammatory disease that affects an estimated 3% of the population in the United States.1 Psoriasis creates a large economic burden for patients and payers; estimates…
Read More
INTRODUCTION Psoriasis is a common chronic inflammatory skin condition that affects 3-4% of the adult United States population. 1 The pathogenesis of psoriasis is multifactorial and thought to be due…
Read More
INTRODUCTION Current treatment of skin psoriasis achieves approximately a 70% reduction in the Psoriasis Area Severity Index (PASI) with combination vitamin analogues plus corticosteroids, with up to 80% of patients…
Read More
INTRODUCTION The recent approval of ivermectin for the treatment of the inflammatory lesions of rosacea is the latest in a series of indications spanning the past 25 years.1,2 The aim…
Read More
